The first-line treatment of esophageal cancer Keytruda combination therapy significantly improved the total survival of patients.

The treatment of esophageal cancer is difficult, and its tumor cells originate in the inner layer of the esophageal system and expand outwards, there are two main types: squamous cell carcinoma and adenocarcinoma.
, esophageal cancer is the seventh most common cancer and the sixth most common cause of death, with a five-year survival rate of only 8% in late-stage patients.
china has the highest incidence of esophageal cancer in the worldChinese, which may be closely related to the "hot eating" eating habits of the chinese people.
china's National Cancer Center, it ranks fourth among deaths from malignant tumors in China.
572,000 esophageal cancer patients worldwide each year, with 508,000 deaths.
, china has about 307,000 esophageal cancer patients and 283,000 deaths each year.
Keytruda is a heavy-weight PD-1 inhibitor developed by Mercedon.
it has been approved in the United States and China as a single drug therapy, second-line treatment of tumor expression PD-L1 (CPS-10) of relapsed localized advanced or metastatic esophageal squamous cell carcinoma patients.
In the KEYNOTE-590 clinical trial, based on an interim analysis conducted by the Independent Data Monitoring Board, Keytruda combined chemotherapy showed significant and clinically significant improvements in OS and PFS in intentional therapy (ITT) population compared to chemotherapy (cisplatin combined 5-fluorouracil).
study also reached a critical secondary endpoint of objective mitigation rate (ORR).
: .Merck's KEYTRUDA® (pembrolizumab) in With With Film Life Great Improved General Survival and Progression-Free Survival Compared With With With Technology in Locally Advanced or First-Line Metastatic Esophageal Cancer. Retrieved August 19, 2020, from.